CN1646695A - Axl受体在诊断和治疗肾病中的应用 - Google Patents

Axl受体在诊断和治疗肾病中的应用 Download PDF

Info

Publication number
CN1646695A
CN1646695A CNA038082365A CN03808236A CN1646695A CN 1646695 A CN1646695 A CN 1646695A CN A038082365 A CNA038082365 A CN A038082365A CN 03808236 A CN03808236 A CN 03808236A CN 1646695 A CN1646695 A CN 1646695A
Authority
CN
China
Prior art keywords
axl
compound
cell
activity
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038082365A
Other languages
English (en)
Chinese (zh)
Inventor
奥尔纳·莫尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quark Pharmaceuticals Inc
Original Assignee
Quark Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quark Biotech Inc filed Critical Quark Biotech Inc
Publication of CN1646695A publication Critical patent/CN1646695A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CNA038082365A 2002-02-12 2003-02-12 Axl受体在诊断和治疗肾病中的应用 Pending CN1646695A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35637402P 2002-02-12 2002-02-12
US60/356,374 2002-02-12

Publications (1)

Publication Number Publication Date
CN1646695A true CN1646695A (zh) 2005-07-27

Family

ID=27734638

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038082365A Pending CN1646695A (zh) 2002-02-12 2003-02-12 Axl受体在诊断和治疗肾病中的应用

Country Status (7)

Country Link
US (3) US20030157573A1 (https=)
EP (1) EP1483400A4 (https=)
JP (1) JP2005517412A (https=)
CN (1) CN1646695A (https=)
AU (1) AU2003223172A1 (https=)
IL (1) IL163547A0 (https=)
WO (1) WO2003068983A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107003301A (zh) * 2014-10-20 2017-08-01 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CN113215157A (zh) * 2021-05-20 2021-08-06 徐州医科大学 特异性靶向人AXL基因的sgRNA及其应用
CN113252911A (zh) * 2021-07-02 2021-08-13 珠海丽珠试剂股份有限公司 SARS-CoV-2中和抗体的检测试剂盒及其应用
US11353465B2 (en) 2017-01-12 2022-06-07 Astute Medical, Inc. Methods and compositions for evaluation and treatment of renal injury and renal failure based on C—C motif chemokine ligand 14 measurement

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223172A1 (en) * 2002-02-12 2003-09-04 Quark Biotech, Inc. Use of the axl receptor for diagnosis and treatment of renal disease
AU2003286746A1 (en) * 2002-10-29 2004-05-25 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis and tumorigenesis
EP1732650A4 (en) 2004-03-27 2008-06-11 Univ Arizona COMPOSITION AND METHOD FOR CANCER TREATMENT
TW200726845A (en) * 2006-01-02 2007-07-16 Nat Defense Medical Ct Biomarker molecular of renal illness and detecting method for the same
EP2079736B1 (en) 2006-12-29 2017-10-18 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as axl inhibitors
WO2009005813A1 (en) * 2007-07-02 2009-01-08 Wyeth Modulators of axl for use in treating bone disorders
US9074192B2 (en) 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
CA2786149C (en) 2010-01-22 2019-11-12 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl signaling in anti-metastatic therapy
WO2013090776A1 (en) * 2011-12-15 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl/gas6 signaling in the treatment of disease
RS55728B1 (sr) 2012-01-31 2017-07-31 Daiichi Sankyo Co Ltd Derivat piridona
EP2626705A1 (en) * 2012-02-13 2013-08-14 Institut d'Investigacions Biomédiques August Pi i Sunyer Use of the soluble form of AXL in the diagnosis and/or prognosis of heart failure syndrome
JP6992960B2 (ja) * 2013-12-02 2022-02-03 ベルゲンビオ アーエスアー キナーゼ阻害剤の用途
US10137173B2 (en) 2014-10-20 2018-11-27 Aravive Biologics, Inc. Antiviral activity of Gas6 inhibitor
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
ES2977788T3 (es) 2017-04-20 2024-08-30 Adc Therapeutics Sa Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco
KR102763266B1 (ko) * 2021-11-30 2025-02-04 충남대학교산학협력단 Axl을 포함하는 지방간 예방 또는 치료용 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
AU697142B2 (en) * 1993-11-23 1998-10-01 Genentech Inc. Protein tyrosine kinases named Rse
AU1518595A (en) * 1994-01-14 1995-08-01 Genentech Inc. Antagonists to insulin receptor tyrosine kinase inhibitor
US5538861A (en) * 1994-07-29 1996-07-23 Amgen Inc. DNA encoding a stimulating factor for the axl receptor
US6211142B1 (en) * 1995-03-10 2001-04-03 Genentech, Inc. Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
US5849585A (en) * 1995-05-10 1998-12-15 Genetech, Inc. Isolating and culturing Schwann cells
US20040102389A1 (en) * 1995-10-26 2004-05-27 Ribozyme Pharmaceuticals, Inc. Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US6235769B1 (en) * 1997-07-03 2001-05-22 Sugen, Inc. Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
US6236769B1 (en) * 1998-01-28 2001-05-22 Cognex Corporation Machine vision systems and methods for morphological transformation of an image with zero or other uniform offsets
US20030149113A1 (en) * 2001-10-12 2003-08-07 Caplan Michael J. Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US20040259247A1 (en) * 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
US20020165158A1 (en) * 2001-03-27 2002-11-07 King George L. Methods of modulating angiogenesis
EP1575976A4 (en) * 2001-11-02 2006-08-23 Insert Therapeutics Inc METHODS AND COMPOSITIONS FOR THE THERAPEUTIC USE OF RNA INTERFERENCE
AU2003223172A1 (en) * 2002-02-12 2003-09-04 Quark Biotech, Inc. Use of the axl receptor for diagnosis and treatment of renal disease
US20030229906A1 (en) * 2002-04-15 2003-12-11 Gelman Irwin H. Methods and compositions for the treatment of disorders of HIV infection
DE602004028587D1 (de) * 2003-01-16 2010-09-23 Univ Pennsylvania ZUSAMMENSETZUNGEN UND VERFAHREN ZUR siRNA-HEMMUNG VON ICAM-1

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107003301A (zh) * 2014-10-20 2017-08-01 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CN107003301B (zh) * 2014-10-20 2019-11-01 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
US11333671B2 (en) 2014-10-20 2022-05-17 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US12099067B2 (en) 2014-10-20 2024-09-24 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US11353465B2 (en) 2017-01-12 2022-06-07 Astute Medical, Inc. Methods and compositions for evaluation and treatment of renal injury and renal failure based on C—C motif chemokine ligand 14 measurement
US12203944B2 (en) 2017-01-12 2025-01-21 Astute Medical, Inc. Methods and compositions for evaluation and treatment of renal injury and renal failure based on C-C motif chemokine ligand 14 measurement
CN113215157A (zh) * 2021-05-20 2021-08-06 徐州医科大学 特异性靶向人AXL基因的sgRNA及其应用
CN113252911A (zh) * 2021-07-02 2021-08-13 珠海丽珠试剂股份有限公司 SARS-CoV-2中和抗体的检测试剂盒及其应用

Also Published As

Publication number Publication date
IL163547A0 (en) 2005-12-18
WO2003068983A1 (en) 2003-08-21
US20090075923A1 (en) 2009-03-19
US20030157573A1 (en) 2003-08-21
EP1483400A4 (en) 2007-07-11
US20090042826A1 (en) 2009-02-12
WO2003068983A9 (en) 2004-12-29
AU2003223172A1 (en) 2003-09-04
JP2005517412A (ja) 2005-06-16
EP1483400A1 (en) 2004-12-08

Similar Documents

Publication Publication Date Title
CN1646695A (zh) Axl受体在诊断和治疗肾病中的应用
CN1678734A (zh) 分化调节试剂及其应用
US7122361B2 (en) Compositions employing a novel human kinase
CN1592625A (zh) G蛋白偶联受体测定
CN1894409A (zh) 人LXRα变体
US20080178307A1 (en) Compositions, organisms and methodologies employing a novel human protein phosphatase
WO2006022628A1 (en) Methods for identifying risk of type ii diabetes and treatments thereof
CN1774634A (zh) 作用于酪氨酸激酶以诊断和治疗骨关节炎的方法和组合物
JP3842130B2 (ja) Ｍａｐキナーゼ経路を活性化するホスファターゼ
HK1077328A (en) Use of the axl receptor for diagnosis and treatment of renal disease
JP2004065194A (ja) 脂肪細胞関連因子の分析方法
CN1934251A (zh) 使用atp7a－调控剂治疗神经变性疾病
CN1871361A (zh) 使用半乳凝集素－2基因内单碱基多态性进行的炎症性疾病的判定方法
US20090136506A1 (en) Conserved Membrane Activator of Calcineurin (CMAC), a Novel Therapeutic Protein and Target
JP4516747B2 (ja) インスリン作用促進能力の検定方法
WO2003052096A1 (en) Mtehod of analyzing gene expression
US20040121383A1 (en) Compositions, organisms and methodologies employing a novel human kinase
CN1737159A (zh) 检测ppn/mg61表达的方法及其应用
CN1930305A (zh) 过氧化物酶体增殖物激活受体α靶基因的使用方法
JP4516746B2 (ja) コレステロールエステル分泌抑制能力の検定方法
EP1619504A1 (en) Novel use of the kinases RSK4 and PAK5
JP2004215503A (ja) 遺伝子発現解析方法
WO2007058336A1 (ja) Rec168を介する肥満細胞の脱顆粒反応抑制物質またはプロスタグランジンＤ２産生抑制物質のスクリーニング方法及び同定方法、並びにそれら物質を含有してなる炎症性疾患の治療剤
Rababa'h Human Signaling Scaffold Protein (mAKAP) Polymorphisms: Role in Heart Failure
KR20200062224A (ko) Slc14a1 변이체 및 그 용도

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CI01 Publication of corrected invention patent application

Correction item: Address

Correct: Tokyo, Japan

False: American California

Number: 30

Volume: 21

Correction item: Applicant

Correct: Taisho Pharmaceutical Co., Ltd.

False: Quark light technologies, Inc.

Number: 30

Volume: 21

CI02 Correction of invention patent application

Correction item: Address

Correct: Tokyo, Japan

False: American California

Number: 30

Page: The title page

Volume: 21

Correction item: Applicant

Correct: Taisho Pharmaceutical Co., Ltd.

False: Quark light technologies, Inc.

Number: 30

Page: The title page

Volume: 21

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT ADDRESS; FROM: QUARK GUANGWU TECHNOLOGY CO.,LTD. CALIFORNIA, USA TO: TAISHO PHARMACEUTICAL CO., LTD. TOKYO, JAPAN

ERR Gazette correction

Free format text: CORRECT: APPLICANT ADDRESS; FROM: QUARK GUANGWU TECHNOLOGY CO.,LTD. CALIFORNIA, USA TO: TAISHO PHARMACEUTICAL CO., LTD. TOKYO, JAPAN

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1077328

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1077328

Country of ref document: HK